SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine: (STO:AEROB)
Continued positive sales development, +88% in the quarter and closing of successful new share issue.
January – June 2012
• Global Net sales grew by 82% to SEK 76.0m (41.8). Adjusted for currency fluctuations, net sales rose by 75% Year over Year (YoY)
• The worldwide number of NIOX MINO® repeat tests sold increased by a total of 50% and for clinical use in the US by 75%
